Monday, 31 October 2011
Fujifilm to manufacture ContraFect biologic
Fujifilm Diosynth Biotechnologies will use its pAVEway advanced protein expression technology at its Billingham, UK, facility to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysine.
Manufacturing Chemist
Lonza to manufacture GenMab's HuMax-TF
Lonza will provide process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility. The antibody, which is expressed using Lonza’s GS Gene Expression System, will be conjugated at Lonza's plant in Visp, CH to a cytotoxic drug to form the antibody drug conjugate.
GEN
Monday, 24 October 2011
Almac to increase manufacturing capacity
Almac is expanding manufacturing capacity to over 30m3 at its Craigavon, UK, headquarters. The company said the facility will include reactor vessels with state of the art clean room product isolation and drying equipment to allow HPAPI manufacture up to 600kg batch size. Almac anticipates that the facility will be built, commissioned and validated within the next two years.
Almac
Layoffs at Corden
Corden Pharma Colorado, the former Roche Colorado facility recently acquired by ICIG, is to lay off 60 of its 260 workers.
Boulder County Business Report
Thursday, 20 October 2011
Almac to expand pharmaceutical development capabilities
Almac will invest £4.5m in the first phase of expanding pharmaceutical development capabilities at its headquarters in Craiavon, Northern Ireland. The new laboratory scale facility, which is due for completion in mid-2012, will provide non-GMP formulation facility for the development and scale-up of solid oral dose drug products using a range of technologies. The second stage of the expansion will add dedicated analytical laboratories before the end of 2012.
Genetic Engineering and Biotechnology News
Carbogen Amcis and Polymun Scientific to team on HPAPI technologies
Carbogen Amcis will collaborate with Polymun Scientific to offer additional services for the development, manufacturing and formulation of HPAPIs. Carbogen Amcis will gain access to Polymun's innovative liposome technology for the formulation of APIs and Polymun will have access to Carbogen Amcis' expertise in the development and manufacture of highly potent APIs.
Carbogen Amcis
Wednesday, 19 October 2011
Hovione collaborates with Bend Research
Hovione and Bend Research will collaborate to offer their clients access to each other's capabilities. Bend Research will offer its clients access to Hovione’s commercial-scale pharmaceutical manufacturing facilities and Hovione clients will have access to Bend Research’s oral drug-delivery, formulation, and engineering expertise.
Bend Research
Monday, 17 October 2011
Angel to establish jv
Angel Biotechnology is to establish a joint venture with Materia Medica Holding (MMH). The jv, which will be 51% owned by MMH and 49% owned by Angel, will commission new product programmes and manage their production in a dedicated GMP unit operated by Angel, on behalf of MMH. To manufacture products for MMH, Angel plans to increase the size of the GMP facility at Cramlington.
Proactive Investors
Profits fall at Aesica
Aesica's pre-tax profit in 2010 fell from £9.7m to £3.4m as sales fell slightly from £84.6m to £83.5m. The company said the closure of its Ponders End facility in London generated exceptional costs of £6.8m, including £3.1m primarily relating to redundancy payments.
Insider Media, Yorkshire
Saltigo to add HPAPI manufacturing capabilities
Saltigo is adding the capabilities to produce potent and highly potent APIs at its Redmond, WA, facility. Andreas Stolle, head of Saltigo's pharma business line, said the kilogram scale facility, aimed at supplying materials for phase I and II, will be available early in 2012. Additionally, Saltigo's Leverkusen site has been accredited by the Japanese Pharmaceuticals and Medical Devices Agency.
Saltigo
Wednesday, 5 October 2011
Carbogen Amcis completes inspection
Carbogen Amcis has successfully completed a US FDA pre-approval inspection for a new high potency drug. for a US multinational. Dishman's managing director JR Vyas said: "Post this approval, we expect business of around $10m per annum from our existing customers."
Money Control
Aesica gets new investor plans expansion
Silverfleet Capital has replaced LDC as the majority investor in Aesica. Silverfleet's investment will enable Aesica to continue its rapid expansion into new markets and achieve its vision of becoming the number one supplier of APIs and formulated products to the global pharmaceutical industry.
Contract Pharma
